Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alk-Abello partners with Schering-Plough on allergy treatments
The agreement gives Schering-Plough exclusive licence rights to develop, market and distribute the grass pollen allergy drug Grazax, as well as treatments for house dust mite allergy and
The agreement gives Schering-Plough exclusive licence rights to develop, market and distribute the grass pollen allergy drug Grazax, as well as treatments for house dust mite allergy and
The study also confirmed the excellent safety and tolerability profile of DP-b99, according to the Israel-based biopharmaceutical company. There was a significant two-fold increase in the number of
The FDA has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as Tenormin. Atenolol is indicated in the management of hypertension, which may
The US subsidiary of Japanese pharmaceutical company Daiichi Sankyo said that, if approved, WelChol will be the first LDL cholesterol-lowering medication also indicated for improving glycemic control. Clinical
However, the approval is subject to certain conditions requested by the FDA. Wyeth currently has problems at its manufacturing plant in Guayama, Puerto Rico, where Pristiq will be
The FDA issued this tentative approval because Exforge has met all the required standards for safety, efficacy and manufacturing quality. Exforge is expected to be available to patients
The agreement in principle provides for a civil resolution, which means that there will be no criminal charges against the company. The settlement, reached with the United States
XL880 is an orally bioavailable small molecule inhibitor of the MET and VEGF receptor tyrosine kinases that are involved in tumor cell growth, migration, and angiogenesis. The multi-center
Combigan has been developed for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension and is already marketed in Europe, Canada, Brazil and Australia.
The FDA’s Office of Generic Drugs has determined Ranbaxy’s simvastatin to be bioequivalent to the listed drug Zocor manufactured by Merck Research Laboratories. Total annualized market sales for